6533b825fe1ef96bd128286f

RESEARCH PRODUCT

Visceral leishmaniasis during pegylated interferon therapy for chronic hepatitis C: first report.

Antonio CascioSpinello AntinoriChiara IariaGiuseppa CostantinoFilippo Ricciardi

subject

Pharmacologymedicine.medical_specialtySide effectbusiness.industryIncidence (epidemiology)medicine.diseaseVirologyGastroenterologyInfectious DiseasesCombined treatmentVisceral leishmaniasisChronic hepatitisPegylated interferonInternal medicinePEGylationMedicinePharmacology (medical)businessleishmaniasismedicine.drug

description

See: Puoti et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antiviral Therapy 2004; 9:627–630.

yearjournalcountryeditionlanguage
2005-07-01
http://hdl.handle.net/11570/1889615